ByteDance Spins Out AI Drug Unit Anew Labs At $1.5B
ByteDance closed a $290 million funding round for Anew Labs, its newly spun-off AI drug discovery unit, at a $1.5 billion valuation, with the TikTok parent retaining 56% ownership.
Company intelligence
As of September 16, 2026, Anew Labs was last valued at $1.5B (TheNextWeb) and has raised at least $290M in equity across 1 sourced funding round.
Anew Labs is an AI drug discovery company spun off from ByteDance.[1] It is headquartered in Shanghai, with offices in San Francisco and Singapore, according to Reuters.[1] The company runs platforms for biomolecular structure prediction and design, antibody design and optimization, and drug discovery.[1] The team built structure-prediction and protein-design models including Protenix and PXDesign.[2] Its pipeline includes a small-molecule drug, a drug targeting a protein on the surface of human cells and two undisclosed targets.[1] One of its four candidates, an AI-designed IL-17 inhibitor, was presented in April 2026 at the American Association of Immunologists meeting in Boston.[2],[1] About 50 core staff moved to the new company with its algorithms, platform and pipeline assets, and ByteDance's Volcano Engine cloud continues to supply computing power.[2]
Is something wrong on this page?
| Date | Round | Amount | Valuation | Lead investors | Source |
|---|---|---|---|---|---|
| Sep 16, 2026 | Funding round | $290M | $1.5Bpost-money | WithIDG CapitalHillhouseGaorong VenturesPrimavera CapitalBoyu Capitalunverified5Y CapitalShanghai Future Industries FundSBP Group | TheNextWeb |
Equity only. “Equity raised” above sums the rounds with a dated, linked source; rumored rounds, tender offers and secondary sales are listed but not counted, and debt financing is listed separately.
In September 2026 Reuters reported, citing people familiar with the matter, that Anew Labs completed a $290 million first external round at a $1.5 billion valuation.[1] HSG (formerly Sequoia China), IDG Capital and Hillhouse's GL Ventures led the round, with 5Y Capital as a co-lead.[1] ByteDance keeps a 56% stake after the round.[1]
In September 2026 Reuters reported, citing people familiar with the matter, that Anew Labs completed a $290 million first external round at a $1.5 billion valuation.[1]
Anew Labs is headquartered in Shanghai, with offices in San Francisco and Singapore, according to Reuters.[1]
Anew Labs is an AI drug discovery company spun off from ByteDance.[1]
Anew Labs has raised at least $290M in equity across 1 sourced funding round tracked by Value Add VC. The most recent was a $290M funding round in September 2026 at a $1.5B post-money valuation, reported by TheNextWeb. Debt financing, tender offers and secondary sales are not counted.
Lead investors in Anew Labs's sourced funding rounds include HongShan (Sequoia China). Per round: its September 2026 funding round was led by HongShan (Sequoia China).
Anew Labs was founded in 2021, according to pharmaphorum.com.
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.